Attleboro, MA, United States of America

Donald Foster

USPTO Granted Patents = 18 

 

 

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 79(Granted Patents)


Location History:

  • Cambridge, MA (US) (2015 - 2022)
  • Attleboro, MA (US) (2016 - 2024)

Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents

Title: Donald Foster: Innovator in RNA Interference and Gene Therapy

Introduction

Donald Foster, an accomplished inventor based in Attleboro, MA, has made significant contributions to the field of RNA interference (RNAi) and gene therapy, holding a remarkable 18 patents. His work primarily focuses on developing innovative solutions to combat genetic disorders through targeted gene silencing.

Latest Patents

Foster's latest patents include groundbreaking inventions such as "Complement component C5 iRNA compositions and methods of use thereof." This invention involves compositions targeting the complement component C5 gene, utilizing double-stranded ribonucleic acid (dsRNA) to inhibit the expression of C5. These methods have potential applications in treating conditions like paroxysmal nocturnal hemoglobinuria.

Another significant invention is the "Angiotensinogen (AGT) iRNA compositions and methods of use thereof," which relates to RNAi agents that target the AGT gene. This innovative approach aims to inhibit AGT gene expression, presenting methods for preventing and treating AGT-associated disorders, including high blood pressure.

Career Highlights

Donald Foster is currently associated with Alnylam Pharmaceuticals, Inc., where he continues his groundbreaking research in RNAi technology. His extensive knowledge and innovative thinking have positioned him as a prominent figure in biotech and pharmaceutical sectors, particularly in developing therapies to address complex genetic diseases.

Collaborations

Throughout his career, Foster has worked alongside notable colleagues such as Martin A. Maier and Klaus Charisse. Their collaborative efforts underscore the importance of teamwork in advancing biotechnology and developing effective treatments based on RNAi technologies.

Conclusion

Donald Foster exemplifies the spirit of innovation that drives the field of genetic research and therapy. His patents stand as a testament to his dedication and creativity in finding viable solutions to challenging medical issues, impacting the lives of many. His ongoing work at Alnylam Pharmaceuticals promises to further enhance our understanding of RNA-based therapies and their applications in modern medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…